Back to News
Market Impact: 0.2
Cullinan Moves CLN-049 Into Phase 2 Development For Relapsed/Refractory AML
Source: Nasdaq
Healthcare & Biotech
Cullinan Therapeutics said the first patient has been dosed in its pivotal Phase 2 study of CLN-049 for relapsed or refractory acute myeloid leukemia. The trial-start milestone is positive, but the article reports no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CGEM0.45
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures